T-Ray Science, Inc., a medical device company committed to commercializing innovative systems for the early detection of cancer announces that shareholders approved a change of the name of the company to Verisante Technology, Inc.
Concurrently, the company’s URL has changed to http://www.verisante.com.
The common shares of the company will commence trading on the TSX Venture Exchange on Tuesday January 18, 2011 under the trading symbol “VRS” and under CUSIP Number 92346G104.
The Verisante Core™ series for lung cancer detection and the Verisante Aura™ for skin cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at VGH. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers, including gastro-intestinal, colorectal and cervical cancers.
“With the company's full commitment towards commercialization of Verisante Aura™ for the early detection of skin cancer and Verisante Core™ for the early detection of lung cancer, the name Verisante Technology better reflects the Company's current focus and business model and seamlessly aligns the Company’s brand with the products themselves,” said Thomas Braun, President and CEO.
Shareholders holding shares in brokerage accounts or in street names will not need to take any action. Registered shareholders will be sent a Letter of Transmittal by the company outlining the procedure to exchange their existing shares for shares evidencing the new name of the company.